Patents by Inventor François-Loïc Cosset

François-Loïc Cosset has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7846429
    Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 7, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francois-Loic Cosset, Roberto Cattaneo
  • Publication number: 20100247497
    Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: —a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and —a second protein which comprises a ligand of the c-Kit receptor.
    Type: Application
    Filed: July 23, 2008
    Publication date: September 30, 2010
    Inventors: François-Loïc Cosset, Els Verhoeyen, Carollne Costa, Cecilia Frecha
  • Patent number: 7442550
    Abstract: A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the group consisting of: a peptide comprising the cyt domain of the envelope protein of the human endogenous retrovirus, HERV-W; a peptide comprising amino acids 448-538 of SEQ ID NO: 1; and a peptide comprising a sequence having, for any series of 20 amino acids, at least 80% identity with amino acids 448-538 of SEQ ID NO: 1. Detection is established by the fusogenic power of the polypeptide, which is demonstrated by syncytia formation.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: October 28, 2008
    Assignees: Biomerieux, Institut National de la Sante et de la Recherche Medicale
    Inventors: Francois Mallet, Francois-Loic Cosset, Jean-Luc Blond, Dimitri Lavillette, Olivier Bouton, Alessia Ruggieri
  • Publication number: 20080227740
    Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 18, 2008
    Inventors: Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francois-Loic Cosset, Roberto Cattaneo
  • Publication number: 20080171027
    Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 17, 2008
    Inventors: Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francois-Loic Cosset, Roberto Cattaneo
  • Patent number: 7317004
    Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: January 8, 2008
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francois-Loic Cosset, Roberto Cattaneo
  • Patent number: 7314868
    Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: January 1, 2008
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francois-Loic Cosset, Roberto Cattaneo
  • Patent number: 7198935
    Abstract: The invention relates to the generation and the use of pestivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of pestivirus virion.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: April 3, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Birke Bartosch, Francois-Loic Cosset
  • Publication number: 20070072191
    Abstract: The invention relates to the generation and the use of pestivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of pestivirus virion.
    Type: Application
    Filed: March 3, 2004
    Publication date: March 29, 2007
    Inventors: Birke Bartosch, Francois-Loic Cosset
  • Publication number: 20060257366
    Abstract: The present invention provides improved chimeric glycoproteins (GPs) and improved lentiviral vectors pseudotyped with those glycoproteins. Also provided are methods and compositions for making such glycoproteins and vectors, and improved methods of in vitro and in vivo transduction of cells with such vectors. Improved chimeric GPs encode the extracellular and transmembrane domains of GALV or RD114 GPs fused to the cytoplasmic tail of MLV-A GP. Vectors pseudotyped with these GAL V/TR and RD 114/TR GP chimeras have significantly higher titers than vectors coated with the parental GPs. Additionally, RD114/TR-pseudotyped vectors are efficiently concentrated and are resistant to inactivation induced by the complement of both human and macaque sera. RD114 GP-pseudotyped lentiviral vectors have particular utility for in vivo gene transfer applications.
    Type: Application
    Filed: April 25, 2003
    Publication date: November 16, 2006
    Inventors: Didier Trono, Francois-Loic Cosset, Virginie Sandrin, Didier Negre, Patrick Salmon
  • Publication number: 20060222661
    Abstract: The invention relates to the generation and the use of hepacivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of hepacivirus virion.
    Type: Application
    Filed: September 12, 2003
    Publication date: October 5, 2006
    Inventors: Birke Bartosch, Francois-Loic Cosset
  • Publication number: 20060051335
    Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
    Type: Application
    Filed: August 18, 2005
    Publication date: March 9, 2006
    Inventors: Stephen Russell, Frances Morling, Adele Fielding, Francois-Loic Cosset, Roberto Cattaneo
  • Publication number: 20040253214
    Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells,
    Type: Application
    Filed: December 10, 2003
    Publication date: December 16, 2004
    Applicant: Mayo Foundation For Medical Education and Research, a Minnesota corporation
    Inventors: Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francois-Loic Cosset, Roberto Cattaneo
  • Patent number: 6750206
    Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
    Type: Grant
    Filed: April 30, 1998
    Date of Patent: June 15, 2004
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francois-Loic Cosset, Roberto Cattaneo
  • Publication number: 20040096972
    Abstract: Disclosed is a plasmid comprising a replicative retroviral genome, characterized in that it contains a psi (&psgr;) sequence, gag and pol sequences originated from the genome of an MLV virus, and a chimeric env sequence. The chimeric env sequence comprises a region corresponding to part of the envelope originating from the genome of an MLV virus and a region corresponding to part of the envelope originating from the genome of a GaLV virus.
    Type: Application
    Filed: October 2, 2003
    Publication date: May 20, 2004
    Applicants: GENETHON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Muriel Audit, Francois-Loic Cosset
  • Publication number: 20040071661
    Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.
    Type: Application
    Filed: October 15, 2003
    Publication date: April 15, 2004
    Inventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, Francois-Loic Cosset
  • Publication number: 20030095947
    Abstract: Compositions and Methods for Elimination of Unwanted Cells Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
    Type: Application
    Filed: April 30, 1998
    Publication date: May 22, 2003
    Inventors: STEPHEN JAMES RUSSELL, FRANCES JOANNE MORLING, ADELE KAY FIELDING, FRANCOIS-LOIC COSSET, ROBERTO CATTANEO
  • Patent number: 6329199
    Abstract: Retroviral vectors which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: December 11, 2001
    Inventors: Michael Pensiero, Mary K. L. Collins, Francois-Loic Cosset, Yasuhiro Takeuchi, Robin A. Weiss
  • Patent number: 5998192
    Abstract: The invention relates to a recombinant viral particle capable of delivering a nucleic acid to mammalian cells, the particle including a member of a first specific binding pair capable of binding to a first receptor expressed on the surface of a cell so as to cause infection thereof, and a surface-exposed member of a second specific binding pair capable of binding to a second receptor generally not expressed on the surface of the cell, such that binding of the viral particle to the second receptor via the member of the second specific binding pair inhibits infection of the cell by the viral particle.
    Type: Grant
    Filed: August 19, 1997
    Date of Patent: December 7, 1999
    Assignee: Medical Research Council
    Inventors: Stephen James Russell, Francois-Loic Cosset, Frances Joanne Bullough, Robin Anthony Weiss, Mary Katharine Levinge Collins
  • Patent number: 5952225
    Abstract: Retroviral which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.
    Type: Grant
    Filed: August 17, 1995
    Date of Patent: September 14, 1999
    Assignees: Genetic Therapy, Inc., Institute of Cancer Research Royal Cancer Hospital
    Inventors: Michael Pensiero, Mary K. L. Collins, Francois-Loic Cosset, Yasuhiro Takeuchi, Robin A. Weiss